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Introduction
Akathisia is a movement disorder characterized by a subjective 
experience of restlessness alongside an urge to move, generating 
repetitive movements1,2. Its clinical presentation can be confusing 
and vague, making the diagnosis often problematic and posing 
an important challenge in clinical practice1. This challenge stems 
not only from its symptoms and difficult treatment, but also from 
the association with aggression and violence, emergence and/or 
worsening of suicidal ideation, insomnia and exacerbation of the 
psychotic illness1,2. 
Akathisia is the most common movement disorder associated 
with psychotropic medication1, primarily antipsychotic drugs, but 
also occurs as a side effect of selective serotonin reuptake inhibitors2. 
Among antipsychotics, first generation agents have a higher risk of 
eliciting akathisia than second generation agents1.
While neurobiological mechanisms underlying akathisia are still 
uncertain, dysfunctions of basal ganglia and striatal circuits have been 
commonly implicated in its development. Gamma-aminobutyric 
acid and serotonin are the neurotransmitters most specifically linked 
to this movement disorder. An imbalance between serotonergic/
noradrenergic and dopaminergic neurotransmitter systems has 
been classically considered as the origin of akathisia. Nonetheless, 
other theories have been proposed, such as an overstimulation of 
the locus ceruleus and D2/D3 receptor occupancy variations in the 
ventral striatum1.
Akathisia is usually classified according to the symptom’s 
development timing. As such, and considering consensual scientific 
entities, there is acute akathisia, subacute/chronic akathisia, tardive 
akathisia and withdrawal akathisia. The first occurs within a few 
days to weeks of antipsychotic drug initiation or dosage increase. 
Chronic akathisia defines an akathisia that has been present for 
several months. As the name suggests, tardive akathisia arises 
late (1-3 months), happening not only during the course of 
neuroleptic treatment, but also after neuroleptic dosage reduction 
or discontinuation. Withdrawal akathisia happens within 2 weeks of 
neuroleptic dosage reduction or discontinuation, typically being self-
limited and resolving in 6 weeks1. As previously stated, the treatment 
of akathisia can be difficult. Typically, two strategies are defended 
when dealing with this issue. The first is a change in medication, 
either reducing the dose of the culprit agent or switching to another 
agent. The second strategy lies with the addition of anti-akathisia 
pharmaceuticals. Many drugs have been proposed to this effect, 
including propranolol, mirtazapine, anticholinergics (Biperiden, 
Benztropine, Trihexyphenidyl), Mianserine, benzodiazepines, 
Cyproheptadine, Amantadine and Clonidine1. More recently, there 
has been a case report showing success of Pregabalin in the treatment 
of akathisia3,4. In this paper, we report one other case of akathisia that 
improved after the introduction of Pregabalin.
Case report
The patient was a 73-year-old man with an ICD-10 diagnosis of 
Bipolar Disorder (F31). He had an history of psychiatric consultations 
as an outpatient in our unit since 2012 and a psychiatric admission in 
2014 due to an antidepressant-induced mania (a selective serotonin 
reuptake inhibitor together with Mirtazapine). He also had an history 
of a subjective inner restlessness with a frequent wish to move around 
“for years” (sic; impossible to stipulate the exact duration), but had 
not been sufficiently disturbing yet, allowing a relatively good quality 
of life. His usual medication included a first and a second-generation 
antipsychotic, an anticonvulsant (acting as a mood stabilizer) and a 
benzodiazepine – check Table 1 for more details.
In 2018, 1 month after an increase in Quetiapine (250 mg/day to 
350 mg/day), he complained of an exacerbation of the aforementioned 
restlessness, with mental unease, which started to have a significant 
impact in his daily activities. It was described as being worse at rest 
and was ameliorated by moving his legs when walking; therefore, he 
found it very difficult to sit still in one place and would constantly 
walk about. The symptoms were not only noticed by him, but also by 
his wife and daughter. The scores on Barnes Akathisia Rating Scale 
(BARS) were 5 in 9 (for Objective Akathisia, Subjective Awareness of 
Restlessness and Subjective Distress) and 4 in 5 (considered “Marked 
Akathisia”, for Global Clinical Assessment of Akathisia). Before a 
treatment towards akathisia was started, patient’s medical history 
was reviewed, and a complete physical and laboratory screening was 
carried out – resulting negative.
The reduction of current Quetiapine was not appropriate in the 
clinical scenario; Cyamemazine withdrawal was not possible due to 
the patient’s severe insomnia and its worsening on previous failed 
attempts on dose decreases; and Propranolol introduction was not 
an option because of an existing medical history of bradycardia. An 
addition of Mirtazapine 15 mg at bedtime was initially tried, but it 
increased the symptoms and had to be stopped after one week due 
Table 1. Usual medication before pregabalin introduction
Breakfast Lunch Dinner Bedtime
Quetiapine 50 mg, slow 
release
1
Quetiapine 300 mg 1
Bromazepam 3 mg 1 1 1
Lamotrigine 200 mg 1
Cyamemazine 40 mg/mL 20 mg
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to symptom severity. Subsequently, Pregabalin 150 mg/day (50 mg, 
three times-a-day) was initiated. Three weeks after Pregabalin was 
started, the patient was observed in a psychiatry consultation, and 
an improvement in akathisia was noted, without significant adverse 
effects related to the new medicine. The patient reported a substantial 
reduction in his inner restlessness and did not complain about the 
need to constantly walk around any longer. A reduction in BARS was 
observed: Objective Akathisia, Subjective Awareness of Restlessness 
and Subjective Distress went from 5/9 to 2/9; and Global Clinical 
Assessment of Akathisia went from 4/5 (Marked Akathisia) to 1/5 
(Questionable Akathisia). A follow-up psychiatry consultation was 
scheduled for 6 months later, where the patient was observed and the 
clinical benefits of Pregabalin were found to be sustained.
Discussion and conclusions
To our knowledge, this was the second observation that reported 
a positive effect of Pregabalin on akathisia3,4. Nonetheless, some 
comparisons between our case report and De Berardis’ case ought to 
be emphasised. Both patients had the diagnosis of Bipolar Disorder 
(our case from ICD-10, and De Berardis’ from DSM-IV). Our patient, 
on the one hand, was a 73-year-old retired male, probably suffered 
from a low-grade or subclinical akathisia aggravated within the first 
month of Quetiapine’s introduction, while also being medicated with 
a first-generation neuroleptic. On the other hand, De Berardis’ patient 
was a 42-year-old housewife, apparently had no history of akathisia-
like symptoms and developed akathisia after the introduction of 
Aripiprazole, seeking medical attention 8 months after the initiation 
of such medication. All things considered, we can affirm that our 
patient possibly represents a case of acute akathisia, whereas De 
Berardis’ may depict a case of chronic akathisia and/or tardive 
akathisia (as the symptom’s development time frame is not clear).
Pregabalin reduces calcium influx through the binding to 
the alpha-2-delta subunit of the presynaptic neuron’s voltage-
gated calcium channels, consequently decreasing neuronal 
hyperexcitability5. As such, Pregabalin reduces the release of several 
neurotransmitters, including serotonin, norepinephrine, glutamate 
and dopamine5,6, what may explain the efficacy of Pregabalin on 
akathisia.
The existence of these case reports may justify the implementation 
of prospective double-blind, placebo-controlled studies in order to 
evaluate, in a robust manner, the efficacy of Pregabalin in akathisia.
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